Pipeline
Delivering advanced medicines in pill formats that are safer for long term use.
Our pipeline is the product of our diverse chemistry, the power of our AI platform, and the expertise of our scientists. We are advancing programs that bring new small molecule solutions to validated disease targets using multiple different mechanisms to enable us to offer alternatives to biologics as well as combination therapies.
Pipeline
Target
Indications
Mechanism
Discovery
Lead Op
IND Enabling
Clinical
NRF2 – MTAI-1025
Transcription factor
Ulcerative Colitis
Crohn’s Disease, COPD
Covalent
Discovery
Lead Op
IND Enabling
Clinical
Clinical
STAT6
Transcription factor
Th2 Mediated Diseases
Allosteric
Discovery
Lead Op
IND Enabling
Clinical
IND Enabling
Transcription factor
Th17 Mediated Diseases
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Lead Op
Biologic replacement
Respiratory
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Lead Op
Biologic replacement
Undisclosed
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Discovery
Th2 Mediated Diseases: Atopic Dermatitis, Asthma
Th17 Mediated Diseases: Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis